NCT02359968View on ClinicalTrials.gov

PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

February 26, 2015

Primary Completion Date

January 8, 2021

Study Completion Date

February 9, 2024

Conditions

Esophageal NeoplasmsGastro-esophageal Junction Cancer

Interventions

DRUG

FOLFOX

radiochemotherapy before surgery

DRUG

CarboP-pacliT

radiochemotherapy before surgery

Trial Locations (10)

59000

University Hospital of Lille, Lille

59020

Centre Oscar Lambret, Lille

Unknown

ICO Paul Papin, Angers

CHU Bordeaux, Bordeaux

Hôpital La Timone, Marseille

Hôpital Nord, Marseille

ICM - Val d'Aurelle, Montpellier

CH Lyon sud, Pierre-Bénite

Centre Eugène Marquis, Rennes

ICO René Gauducheau, Saint-Herblain

All Listed Sponsors

collaborator

National Cancer Institute, France

OTHER_GOV

lead

Centre Oscar Lambret

OTHER

NCT02359968 - PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer | Biotech Hunter | Biotech Hunter